Optherion

Optherion’s intellectual property is based on genetic discoveries linking certain genes to AMD and orphan renal diseases strongly influenced by components of the alternative complement system. Sequenom is currently marketing a predictive test based on Optherion technology that identifies patients who are predisposed to late stage age-related macular degeneration.

Meanwhile, Baxter, which acquired the rights to Optherion’s therapeutic program via an asset purchase and license agreement, is exploring recombinant and plasma-derived complement Factor H as a therapeutic targeting the treatment of AMD.

Optherion

New Haven, CT

02.09.2010
Sequenom licenses worldwide rights to develop age-related macular…

Read More

02.09.2010
Sequenom licenses worldwide rights to develop age-related macular…

Read More